What is the function of the ischemia modified albumin assay kit

The function of the ischemic modified albumin assay kit is to quantitatively determine the content of ischemic modified albumin (IMA) in human serum in vitro. Its core value is to assist in the diagnosis of myocardial ischemic diseases, exclude acute coronary syndrome (ACS), and evaluate disease risk stratification. The specific functions are as follows:

1. Core function: Early auxiliary diagnosis of myocardial ischemia

High early sensitivity

IMA can increase 5-10 minutes after myocardial ischemia occurs and reach its peak within 1-2 hours, significantly earlier than traditional myocardial injury markers (such as troponin). Its sensitivity in diagnosing myocardial infarction is as high as 98.8%, which can detect the reversible stage of myocardial ischemia earlier and strive for a treatment window for clinical practice.

Distinguish between ischemia and necrosis

IMA is a biomarker of myocardial ischemia, while traditional biomarkers such as troponin and CK-MB reflect myocardial necrosis.

. The combined detection of the two can reduce the missed diagnosis rate of acute coronary syndrome (ACS) and achieve full chain monitoring of ischemia necrosis.

II. Clinical Application Scenarios

Exclusion Diagnosis of ACS

For chest pain patients, if the electrocardiogram is normal but myocardial ischemia is suspected, IMA detection can be used as an exclusion diagnostic tool.

. For example, when transient ischemia is not captured by electrocardiogram, an increase in IMA can indicate the presence of myocardial ischemia and avoid missed diagnosis.

Screening of high-risk groups

Regular IMA testing of high-risk groups of coronary heart disease (such as hypertension, diabetes, smokers) can detect asymptomatic myocardial ischemia early and intervene in time to prevent myocardial infarction.

Disease monitoring and efficacy evaluation

For patients diagnosed with coronary heart disease, regular monitoring of IMA levels can reflect treatment effectiveness.

. If IMA continues to rise, it may indicate disease progression or inadequate treatment, and the plan needs to be adjusted.

III. Mechanism of action: Detection based on changes in albumin structure

Biochemical basis of ischemic modification

During myocardial ischemia/reperfusion, free radicals destroy the amino acid sequence of serum albumin, leading to a decrease in its binding ability with transition metals such as cobalt and copper.

. The albumin with this structural change is called IMA.

Detection principle

The reagent kit quantifies IMA by measuring changes in the binding ability between albumin and cobalt.

. For example:

Albumin cobalt binding method: using cobalt sulfate to bind with albumin, unbound cobalt ions react with dithiothreitol (DTT) to develop color, and the color depth is inversely proportional to the IMA content. ELISA method: The double antibody sandwich method is used to measure the absorbance and calculate the IMA concentration using an enzyme-linked immunosorbent assay (ELISA) reader.

IV. Limitations

Non diagnostic evidence

Elevated IMA only indicates the possibility of myocardial ischemia and cannot diagnose acute myocardial infarction alone. It needs to be combined with electrocardiogram, troponin, and other comprehensive judgments.

.

Interference factors

Hemolytic samples may affect the test results and should be avoided.

. In addition, certain diseases such as cirrhosis and renal insufficiency may lead to false elevation of IMA, which needs to be ruled out in conjunction with clinical practice.